These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 24009294

  • 1. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
    Esteghamati A, Noshad S, Jarrah S, Mousavizadeh M, Khoee SH, Nakhjavani M.
    Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294
    [Abstract] [Full Text] [Related]

  • 2. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial.
    Saklayen MG, Gyebi LK, Tasosa J, Yap J.
    J Investig Med; 2008 Apr; 56(4):714-9. PubMed ID: 18382267
    [Abstract] [Full Text] [Related]

  • 3. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA, Gariani K, Martin PY.
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [Abstract] [Full Text] [Related]

  • 4. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F.
    J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
    [Abstract] [Full Text] [Related]

  • 5. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF.
    Cochrane Database Syst Rev; 2014 Apr 29; (4):CD007004. PubMed ID: 24782282
    [Abstract] [Full Text] [Related]

  • 6. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U, Chaisuvannarat V.
    J Med Assoc Thai; 2009 May 29; 92(5):611-7. PubMed ID: 19459520
    [Abstract] [Full Text] [Related]

  • 7. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
    Sato A, Hayashi K, Saruta T.
    Am J Hypertens; 2005 Jan 29; 18(1):44-9. PubMed ID: 15691616
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
    Kim HY, Bae EH, Ma SK, Kim SW.
    Kidney Blood Press Res; 2014 Jan 29; 39(6):573-80. PubMed ID: 25531940
    [Abstract] [Full Text] [Related]

  • 10. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV, Dass EE.
    Indian J Pharmacol; 2015 Jan 29; 47(2):148-52. PubMed ID: 25878372
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 29; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 14. [Renoprotective effect of triple therapy with low-dose angiotensin receptor blocker, low-dose diuretic and Ca-antagonist in hypertensive type 2 diabetic patients with overt nephropathy].
    Kuriyama S, Tomonari H, Ohtsuka Y, Ohkido I, Hosoya T.
    Nihon Jinzo Gakkai Shi; 2003 Jan 29; 45(4):367-71. PubMed ID: 12806973
    [Abstract] [Full Text] [Related]

  • 15. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review.
    Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ.
    Am J Kidney Dis; 2008 Feb 29; 51(2):199-211. PubMed ID: 18215698
    [Abstract] [Full Text] [Related]

  • 16. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep 29; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

  • 17. Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy.
    Sun LJ, Sun YN, Shan JP, Jiang GR.
    J Diabetes Investig; 2017 Jul 29; 8(4):609-618. PubMed ID: 28107779
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J.
    Diabet Med; 2007 May 29; 24(5):486-93. PubMed ID: 17367311
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.